News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The symposium was organized to provide an opportunity to highlight the advances of aortic surgery and to discuss the future of aortic aneurysm management.
Both products are broad-spectrum, foliar insecticides used across wide range of crops
The second day of Arogya Manthan 2022 had panel discussions with eminent thought leaders from relevant public and private sector organizations
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
AB PMJAY has been successful in providing quality health services to the beneficiaries who come from weak financial backgrounds
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Subscribe To Our Newsletter & Stay Updated
